All News

Under the agreement, Bristol Myers Squibb obtains Mirati’s entire portfolio, including Krazati (adagrasib) for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.

Offerings include treatment plans for a considerable number of illnesses and conditions, company says.

The EVOKE-01 trial compared Trodelvy with docetaxel for the treatment of patients with metastatic or advanced non-small cell lung cancer who progressed on or following platinum-based chemotherapy and checkpoint inhibitor therapy.

NK010 is reportedly the first Chinese trial of its kind to be approved by the FDA.

Data utilization in real-time targeting is a linchpin for success in navigating the intricacies of contemporary pharmaceutical marketing dynamics.

The Osteoboost device has been shown to slow the loss of bone strength and density in postmenopausal women with osteopenia.

Opdivo plus Yervoy shows promise in treating patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer.

With a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.

The biosimilar Cimerli carries the interchangeability designation for the treatment of wet age-related macular degeneration, diabetic macular edema, macular edema following retinal vein occlusion, myopic choroidal neovascularization, and diabetic retinopathy.

According to the university, new nanotech scaffolding can be used to support tissue growth.

Lutathera plus long-acting release octreotide lowered the risk of disease progression or death by 72% in patients with somatostatin receptor-positive well-differentiated grade 2/3 advanced gastroenteropancreatic neuroendocrine tumors.

In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.

Will the FDA ultimately step in and mandate a credible effort to eradicate the mindset that long-term adherence is not achievable?

Novocure’s tumor-treating fields plus standard-of-care therapies is under evaluation in patients with non-small cell lung cancer following disease progression on or after platinum-based treatment.

Sun Pharmaceutical Industries will purchase Taro's outstanding shares for $43 each, which will total $348 million.

Pivmecillinam has already been approved in Europe to treat uncomplicated urinary tract infections.

NX-5948 is under evaluation for for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma following at least two lines of therapy that includes a BTK inhibitor and a BCL2 inhibitor.

In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Bloomlife’s MFM-Pro is a prescription-based wearable device that can track the maternal and fetal heart rate.

HyQvia is the only subcutaneous immune globulin infusion that can be administered once per month.

Researchers believe low numbers in the use of direct-to-consumer healthcare services could rapidly trend up.

Vertex Pharmaceuticals' and CRISPR Therapeutics’ Cas9 therapy Casgevy approved as a one-time treatment for transfusion-dependent beta thalassemia on the heels of its approval last month for sickle cell disease.

Generative artificial intelligence, key new product launches, and the evolution of the go-to-market model are among key trends to watch in the year ahead.

Company displayed findings at the 2024 Winter Clinical Dermatology Conference in Hawaii demonstrating significant improvements in atopic dermatitis and seborrheic dermatitis.

New analysis for 2023 shows signs of post-pandemic recovery; breast cancer remains most studied disease area.

Soaring healthcare costs show little sign of slowing in 2024, with concerns growing about the affordability of medications and medical services.

Study highlights how AI can identify trends and connections that can predict how new patients might respond to therapies.

Dupixent is an IL-4 receptor alpha antagonist that has been approved for the treatment of adults with moderate-to-severe atopic dermatitis, as well as asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis.